- Nanobiotix reported half year 2026 results with revenue of €5.55 million and a net loss of €34.29 million, with basic and diluted loss per share from continuing operations at €0.70.
- The sharp gap between modest revenue and a much larger loss highlights the pressure on Nanobiotix to fund development while commercial income remains limited.
- This article considers how Nanobiotix's widened half year loss may influence the investment narrative investors have been using so far.
Nanobiotix Investment Narrative Recap
To own Nanobiotix, you need to believe its radiotherapy activated NBTXR3 platform can eventually support meaningful treatment use and that today’s heavy R&D bill is a trade off for that opportunity. The latest half year figures, with €5.55 million of revenue and a €34.29 million loss, keep the story squarely in funding and execution territory.
The key near term catalyst still sits with clinical progress and partner execution around Johnson & Johnson led programs like NANORAY 312 and CONVERGE. The sharply wider loss increases sensitivity to any delay or setback in those trials. Funding remains the biggest operational risk if losses stay elevated and non dilutive capital proves insufficient.
The September Phase 1 lung cancer update is the announcement that ties most directly back to that earnings print. It shows Nanobiotix continuing to build a safety and efficacy dossier around JNJ 1900 NBTXR3 across solid tumors, with all 24 patients treated and dose limiting toxicities avoided for the product. That is relevant because the entire income story leans on this platform.
Those data points also matter for the key catalyst investors are watching: the progression and potential future readouts from larger Johnson & Johnson sponsored trials. Each clean safety signal and sign of local control in smaller studies can influence how partners prioritize head and neck and lung programs. The risk, given the widened loss, is that any disappointing results or slower expansion of indications would leave Nanobiotix carrying high costs with fewer levers to offset them in the near term.
For Nanobiotix, analysts are working off assumptions that annual revenue could reach €88.2 million and earnings €32.6 million by 2029. This implies forecast revenue growth of 39.4% per year and an earnings swing of about €56.6 million from current earnings of a €24.0 million loss.
Uncover how Nanobiotix's fair value indicates a 79% potential upside to its current price, which could narrow quickly if sentiment around Nanobiotix improves.
Exploring Other Perspectives
One alternate lens focuses squarely on revenue pressure rather than trial progress. The most cautious analysts were modelling only €2.5 million of sales and about €161.8 thousand of earnings by 2029, even before this half year loss. That paints a far more pessimistic Nanobiotix story and invites you to compare several conflicting forecasts for yourself.
Explore 3 other Nanobiotix fair value estimates, including one that suggests it could be worth just €40.00!
The Verdict Is Yours
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Nanobiotix research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Nanobiotix. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Nanobiotix's overall financial health at a glance.
Looking For More Ideas Beyond Nanobiotix?
If Nanobiotix has sharpened your view on risk, funding and clinical milestones, it can be useful to compare that profile with other businesses screened by consistent criteria on Simply Wall St.
- If capital preservation sits high on your list, you might start with a set of companies that screen as relatively lower risk by checking out 226 resilient stocks with low risk scores.
- If you are hunting for quality at a reasonable price, you can review a curated group of potentially underpriced opportunities through the 190 high quality undervalued stocks.
- If balance sheet strength matters most to you, you can compare businesses with healthier finances using the list of solid balance sheet and fundamentals (201 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com